龟鹿二仙胶对晚期结直肠癌患者免疫细胞因子、TGF-β1/Smad信号通路的作用研究  

Study on the Effect of Guilu Erxian Glue on Immune Cytokines and TGF-β1/Smad Signaling Pathway in Patients with Advanced Colorectal Cancer

作　　者：徐炜[1] 王安镅[1] 王文龙 陈江锋 王际云[1] XU Wei;WANG An-mei;WANG Wen-long;CHEN Jiang-feng;WANG Ji-yun(Department of Integrated Traditional Chinese and Western Medicine Oncology,Hangzhou Cancer Hospital(Wushan Campus of Hangzhou First People's Hospital Affiliated to West Lake University School of Medicine),Hangzhou,Zhejiang,310002,China)

机构地区：[1]杭州市肿瘤医院(西湖大学医学院附属杭州市第一人民医院吴山院区)中西医结合肿瘤科,浙江杭州310002

出　　处：《现代生物医学进展》2024年第21期4090-4092,共3页Progress in Modern Biomedicine

基　　金：浙江省中医药科学研究基金项目(2022ZB287)。

摘　　要：目的:探讨龟鹿二仙胶对晚期结直肠癌患者免疫细胞因子、转化生长因子β1(TGF-β1)/果蝇母本抗生存因子蛋白(Smad)信号通路的作用。方法:根据双色球法将82例晚期结直肠癌患者分为对照组和观察组,各为41例。对照组接受FOLFIRI方案化疗,观察组接受龟鹿二仙胶、FOLFIRI方案化疗。比较两组治疗前后中医证候积分、免疫细胞因子指标、血清TGF-β1/Smad信号通路指标,同时观察两组不良反应发生情况。结果:与对照组治疗后相比,观察组中医证候(乏力明显、食欲降低、腰膝酸软、气短、大便溏薄)积分、CD8+和血清TGF-β1、Smad3水平更低,血清Smad7水平、CD4+、自然杀伤(NK)细胞、CD4+/CD8+更高(P<0.05)。对照组(41.46%)、观察组(29.27%)不良反应发生率对比未见差异(P>0.05)。结论:龟鹿二仙胶可能通过调节免疫细胞因子、抑制TGF-β1/Smad信号通路从而辅助改善晚期结直肠癌患者的临床症状。Objective:To investigate the effect of Guilu Erxian Glue on immune cytokines and transforming growth factor-β1(TGF-β1)/Drosophila mothers against decapentaplegic protein(Smad)signaling pathway in patients with advanced colorectal cancer.Methods:82 patients with advanced colorectal cancer were divided into control group and observation group according to the two-color ball method,41 cases each.Control group received FOLFIRI regimen chemotherapy,and observation group received Guilu Erxian Glue and FOLFIRI regimen chemotherapy.The traditional Chinese medicine syndrome scores,immune cytokines and serum TGF-β1/Smad signaling pathway indexes in two groups before and after treatment were compared,and the incidence of adverse reactions in two groups was observed.Results:Compared with control group after treatment,the scores of traditional Chinese medicine syndromes(obvious fatigue,decreased appetite,soreness and weakness of waist and knees,shortness of breath,thin stool),CD8+and serum TGF-β1,Smad3 levels in observation group were lower,and serum Smad7 levels,CD4+,natural killer(NK)cells,CD4+/CD8+were higher(P<0.05).There was no difference in the incidence of adverse reactions between control group(41.46%)and observation group(29.27%)(P>0.05).Conclusion:Guilu Erxian Glue may assist in improving the clinical symptoms of patients with advanced colorectal cancer by regulating immune cytokines and inhibiting TGF-β1/Smad signaling pathway.

关 键 词：龟鹿二仙胶 晚期结直肠癌 免疫细胞因子 TGF-Β1/SMAD信号通路 

分 类 号：R735.35[医药卫生—肿瘤]